At present, it is well-established that IgA, IgG and Ig-LC MGUS may progress to smoldering multiple myeloma (SMM), which has a prevalence of 0.53% of adults >40 years [8], and (clinical/symptomatic) multiple myeloma (MM) at a rate of ≈1%/year, while SMM cases progress to MM at a higher rate of ≈10%/year [3, 9–11]. The gene discussed is CD79A; the disease is plasma cell myeloma.